Investigational drug · Phase 2
TC011
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL).
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "TC011"
First trial start
2023
Aug 3, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TC011", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed Large B-cell Lymphoma
- Refractory Large B-cell Lymphoma
- Diffuse Large B-cell Lymphoma (DLBCL)
- High-grade B-cell Lymphoma (HGBL)
- Transformed Follicular Lymphoma (TFL)
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "TC011" as an intervention, largest first.
TICAROS Co., Ltd.Industry
NCT07473167 · 98 participants (planned) · Start Aug 3, 2023 · Primary completion Feb 11, 2028
Drug: TC011 · For: Relapsed Large B-cell Lymphoma; Refractory Large B-cell Lymphoma; Diffuse Large B-cell Lymphoma (DLBCL) and 3 more
Sites: Seoul, South Korea
TICAROS Co., Ltd.Industry
NCT07360288 · 40 participants (planned) · Start Mar 1, 2026 · Primary completion May 31, 2028
Drug: TC011 single-arm · For: Follicular Lymphoma (FL)
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Relapsed Large B-cell Lymphoma
- CRC01Phase 22 trials
Curocell Inc. · Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.